PDF《北斗嘉药业股份有限公司》

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北斗嘉药业股份有限公司 BAYTACARE PHARMACEUTICAL CO., LTD.* (a joint stock limited company incorporated in the People'

s Republic of China) (Stock Code: 8197) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR END

31 DECEMBER

2018 Reference is made to the notice of board meeting dated

8 March

2019 and

15 April

2019 (the notice of board meeting ). Unless otherwise defined, terms used in this announcement shall have the same meanings as those in the notice of board meeting. The board ( Board ) of directors ( Directors ) of Baytacare Pharmaceutical Co., Ltd (the Company , together with its subsidiaries, the Group ) hereby announces the annual results of the Group for the year ended

31 December 2018. This announcement, containing the full text of the

2018 annual report of the Company (the

2018 Annual Report ), complies with the relevant requirements of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the GEM Listing Rules ) in relation to information to accompany preliminary announcements of the annual results. In the meeting of the Board held on

29 April

2019 (the Board Meeting ), it was resolved that no dividend be paid. The

2018 Annual Report has been approved by the Board in the Board Meeting. The printed version of the

2018 Annual Report will be dispatched to the shareholders of the Company and will be published on the websites of the Stock Exchange at www.hkexnews.hk and the Company'

s website at www.baytacare.com in due course. By Order of the Board Baytacare Pharmaceutical Co., Ltd.* Fang Yao Chairman Shenzhen, People'

s Republic of China,

29 April

2019 *? for identification purposes only C

1 C CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ( GEM ) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE STOCK EXCHANGE ) GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report. This report, for which the directors (the Directors ) of Baytacare Pharmaceutical Co., Limited (the Company ) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the GEM Listing Rules ) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, there are no other matters the omission of which would make any statement herein or this report misleading. In this report, if there is any inconsistency between the Chinese names of the entities or enterprises established in China and their English translations, the Chinese names shall prevail. English translation of names in Chinese which are marked with * is for identification purpose only. Page Corporate Information